Join over 2,000+ Investors
Register now and embark on your journey to informed and successful investing.
BCYC | US
1.04
4.61%
Healthcare
Biotechnology
30/06/2024
04/10/2024
23.60
22.39
23.61
22.23
Bicycle Therapeutics plc a clinical-stage biopharmaceutical company develops a class of medicines for diseases that are underserved by existing therapeutics. It is developing BT1718 a bicycle toxin conjugate (BTC) which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; BT5528 a BTC that is in a Phase I/II clinical trial targeting Ephrin type-A receptor 2; and BT8009 which is in Phase I/II clinical trial targeting Nectin-4. The company also develops THR-149 a plasma kallikrein inhibitor for the treatment of diabetic macular edema; BT7480 a Bicycle tumor-targeted immune cell agonist (TICA) targeting Nectin-4 and agonizing; BT7455 an EphA2/CD137 Bicycle TICA; and BT7401 a multivalent CD137 agonist. In addition it collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas such as anti-infective cardiovascular dementia central nervous system neuromuscular and respiratory indications. The company has a clinical trial and license agreement with the Cancer Research Technology Limited and Cancer Research UK; research collaboration agreements with AstraZeneca AB Sanofi Oxurion NV and the Dementia Discovery Fund as well as with Ionis Pharmaceuticals Inc.; and a discovery collaboration and license agreement with Genentech Inc. for the discovery and development of Bicycle peptides for multiple immuno-oncology targets as well as strategic collaboration with Bayer for developing Novel Targeted Radionuclide Therapies in Oncology. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge the United Kingdom.
View LessPositive Momentum
Low Debt to Equity (< 0.25)
Low Debt to Asset (< 0.2)
Value Stock (Price to Book < 3)
Smallcap (300M - 2B USD)
High Market Beta (> 0.8)
Weak Operating Margin (< 10%)
Declining Revenue (< 0%)
Weak Sharpe Ratio (< 0.3)
Bullish: Stable Volatility (6-month <= 1-month volatility) is positive for the stock performance.
10 days
40.5%1 month
106.7%3 months
74.6%6 months
62.9%-
-
1.83
0.05
0.04
-2.14
17.25
-
-176.75M
1.63B
1.63B
-
-498.31
-
-17.90
-30.24
7.27
5.36
Short-term: Bearish (SMA10D < SMA1M)
Intermediate-term: Bullish (SMA1M > SMA3M)
Long-term: Bullish (SMA6M > SMA12M)
Range10D
4.63
Range1M
8.18
Range3M
8.93
Rel. volume
0.85
Price X volume
9.28M
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
MannKind Corporation | MNKD | Biotechnology | 6.49 | 1.78B | 3.18% | 124.00 | -149.80% |
Certara Inc. | CERT | Biotechnology | 11.09 | 1.78B | -2.46% | n/a | 29.96% |
Kiniksa Pharmaceuticals Ltd | KNSA | Biotechnology | 24.48 | 1.74B | -0.20% | n/a | 2.62% |
Recursion Pharmaceuticals Inc. Class A Common Stock | RXRX | Biotechnology | 6.11 | 1.72B | 0.00% | n/a | 15.38% |
Arvinas Inc | ARVN | Biotechnology | 24.96 | 1.71B | 1.05% | n/a | 0.38% |
PROK | PROK | Biotechnology | 1.695 | 1.65B | 3.04% | n/a | -0.69% |
NewAmsterdam Pharma Company N.V. Ordinary Shares | NAMS | Biotechnology | 18.22 | 1.64B | 4.53% | n/a | 0.15% |
Ardelyx Inc | ARDX | Biotechnology | 6.82 | 1.61B | -1.59% | n/a | 71.36% |
Syndax Pharmaceuticals Inc | SNDX | Biotechnology | 18.82 | 1.60B | -3.19% | n/a | 0.26% |
BioCryst Pharmaceuticals Inc | BCRX | Biotechnology | 7.58 | 1.57B | 2.71% | n/a | -178.85% |
Name | Ticker | Industry | Close | Marketcap | Day Return | PE Ratio | Debt to Equity |
---|---|---|---|---|---|---|---|
Fox Factory Holding Corp | FOXF | Recreational Vehicles | 40.42 | 1.68B | 0.17% | 42.66 | 64.69% |
Winnebago Industries Inc | WGO | Recreational Vehicles | 57.84 | 1.66B | 0.98% | 21.48 | 56.33% |
Steelcase Inc | SCS | Building Products & Equipment | 12.97 | 1.47B | 0.78% | 12.50 | 65.47% |
REV Group Inc | REVG | Recreational Vehicles | 27.56 | 1.43B | 0.00% | 6.15 | 63.13% |
Janus International Group Inc. | JBI | Building Products & Equipment | 9.79 | 1.42B | 2.73% | 11.54 | 116.21% |
Pitney Bowes Inc | PBI | Building Products & Equipment | 6.92 | 1.24B | 1.91% | n/a | -571.93% |
ARLO TECHNOLOGIES INC | ARLO | Building Products & Equipment | 11.47 | 1.15B | 0.09% | n/a | 19.46% |
Camping World Holdings Inc | CWH | Recreational Vehicles | 23.44 | 1.06B | -0.38% | n/a | 3644.76% |
Malibu Boats Inc | MBUU | Recreational Vehicles | 39.7 | 793.63M | -0.68% | n/a | 1.50% |
Latham Group Inc. | SWIM | Building Products & Equipment | 6.64 | 767.43M | 0.00% | 61.27 | 77.00% |
Parameter | Company | Industry | Indicator |
---|---|---|---|
Enterprise to EBITDA | -2.14 | 0.76 | Cheaper |
Ent. to Revenue | 17.25 | 3,674.48 | Cheaper |
PE Ratio | - | 38.01 | - |
Price to Book | 1.83 | 14.10 | Cheaper |
Dividend Yield | - | 2.22 | - |
Std. Deviation (3M) | 74.63 | 74.67 | Par |
Debt to Equity | 0.05 | -1.82 | Expensive |
Debt to Assets | 0.04 | 0.26 | Cheaper |
Market Cap | 1.63B | 3.73B | Emerging |